Pathology & Oncology Research

, Volume 13, Issue 4, pp 360–364 | Cite as

Factors influencing serum concentration of CA125 and CA15-3 in Iranian healthy postmenopausal women

  • Alamtaj Samsami Dehaghani
  • Alireza Fotouhi Ghiam
  • Marjan Hosseini
  • Sareh Mansouri
  • Abbas Ghaderi


Screening for breast and ovarian cancers are required due to the late stage at diagnosis and poor survival. Serum CA125 and CA15-3 are important cancer-detecting agents in patients with ovarian and breast cancers, respectively. Elevation of CA125 and CA15-3 level correlates with malignant and non-malignant conditions. Moreover, a series of individual characteristics affect the serum level of these markers. The objective of the present study was to evaluate CA125 and CA15-3 levels in cancer-free postmenopausal women to investigate the impacts of patient parameters on the serum level of these markers. 203 subjects were studied prospectively. Serum CA125 and CA15-3 assessment was done subsequent to the direct interview. The associations between marker levels and presenting features were examined. CA125 and CA15-3 levels were elevated in 35 (17.2%) and 12 (5.9%) of persons, respectively. A higher CA125 level was associated with advanced age (p=0.046), while a lower level was correlated with hormone replacement therapy (HRT) and having smoking habits (p=0.000 andp=0.01, respectively). CA15-3 level was remarkably lower amongst oral contraceptive (OCP) users (p=0.03). Serum marker levels were not significantly related to menarche age, age at menopause, height, weight, BMI and parity. Serum CA125 is imperative indicator for malignancies of the ovary; however, personal and medical factors influence its serum level. A fair interpretation of results must be due to an accurate attention to the individual characteristics.

Key words

breast health menopause cancer 


Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.


  1. 1.
    Taechakraichana N, Jaisamrarn U, Panyakhamlerd K, Chaikittisilpa S, Limpaphayom KK: Climacteric: concept, consequence and care. J Med Assoc Thai 85:S1–15, 2002.PubMedGoogle Scholar
  2. 2.
    Rymer J, Morris EP: Extracts from “Clinical evidence”: Menopausal symptoms. BMJ 321: 1516–1519, 2000.PubMedCrossRefGoogle Scholar
  3. 3.
    van Asselt KM, Kok HS, Putter H, Wijmenga C, Peeters PH, van der Schouw YT, Grobbee DE, te Velde ER, Mosselman S, Pearson PL: Linkage analysis of extremely discordant and concordant sibling pairs identifies quantitative trait loci influencing variation in human menopausal age. Am J Hum Genet 74: 444–453, 2004.PubMedCrossRefGoogle Scholar
  4. 4.
    Jamjan L, Jerayingmongkol P: Self-image of people in their fifties. Nurs Health Sci 4:A4, 2002.Google Scholar
  5. 5.
    Pike MC, Pearce CL, Wu AH: Prevention of cancers of the breast, endometrium and ovary. Oncogene 23: 6379–6391, 2004.PubMedCrossRefGoogle Scholar
  6. 6.
    Jacobs IJ, Menon U: Progress and challenges in screening for early detection of ovarian cancer. Mol Cell Proteomics 3: 355–366, 2004.PubMedCrossRefGoogle Scholar
  7. 7.
    Crump C, McIntosh MW, Urban N, Anderson G, Karlan BY: Ovarian cancer tumor marker behavior in asymptomatic healthy women: implications for screening. Cancer Epidemiol Biomarkers Prev 9: 1107–1111, 2000.PubMedGoogle Scholar
  8. 8.
    Public Health Service. Healthy people 2010: National health promotion and disease prevention objectives — full report with commentary. Washington, DC: U.S. Department of Health and Human Services, 2000.Google Scholar
  9. 9.
    Maeda T, Inoue M, Koshiba S, Yabuki T, Aoki M, Nunokawa E, et al: Solution structure of the SEA domain from the murine homologue of ovarian cancer antigen CA125 (MUC16). J Biol Chem 279: 13174–13182, 2004.PubMedCrossRefGoogle Scholar
  10. 10.
    Bast RC Jr: Status of tumor markers in ovarian cancer screening. J Clin Oncol 21: 200–205, 2003.CrossRefGoogle Scholar
  11. 11.
    Zidan J, Hussein O, Basher W, Zohar S: Serum CA125: a tumor marker for monitoring response to treatment and follow-up in patients with non-Hodgkin’s lymphoma. Oncologist 9: 417–421, 2004.PubMedCrossRefGoogle Scholar
  12. 12.
    Taylor-Papadimitriou J, Burchell JM, Plunkett T, Graham R, Correa I, Miles D, Smith M: MUC1 and the immunobiology of cancer. J Mammary Gland Biol Neoplasia 7: 209–221, 2002.PubMedCrossRefGoogle Scholar
  13. 13.
    Clinton SR, Beason KL, Bryant S, Johnson JT, Jackson M, Wilson C, Holifield K, Vincent C, Hall M: A comparative study of four serological tumor markers for the detection of breast cancer. Biomed Sci Instrum 39: 408–414, 2003.PubMedGoogle Scholar
  14. 14.
    Seregni E, Botti C, Bajetta E, Ferrari L, Martinetti A, Nerini-Molteni S, Bombardieri E: Hormonal regulation of MUC1 expression. Int J Biol Markers 14: 29–35, 1999.PubMedGoogle Scholar
  15. 15.
    O’Rourke J, Mahon SM: A comprehensive look at the early detection of ovarian cancer. Clin J Oncol Nurs 7: 41–47, 2003.PubMedCrossRefGoogle Scholar
  16. 16.
    Kayaba H: Tumor markers: essential diagnostic tools for radiologists. Nippon Igaku Hoshasen Gakkai Zasshi 63: 133–139, 2003.PubMedGoogle Scholar
  17. 17.
    Lu KH, Patterson AP, Wang L, Marquez RT, Atkinson EN, Baggerly KA, et al: Selection of potential markers for epithelial ovarian cancer with gene expression arrays and recursive descent partition analysis. Clin Cancer Res 10: 3291–3300, 2004.PubMedCrossRefGoogle Scholar
  18. 18.
    Green BB, Taplin SH: Breast cancer screening controversies. J Am Board Fam Pract 16: 233–241, 2003.PubMedCrossRefGoogle Scholar
  19. 19.
    Pauler DK, Menon U, McIntosh M, Symecko HL, Skates SJ, Jacobs IJ: Factors influencing serum CA125II levels in healthy postmenopausal women. Cancer Epidemiol Biomarkers Prev 10: 489–493, 2001.PubMedGoogle Scholar
  20. 20.
    Lopez LA, Del Villar V, Ulla M, Fernandez F, Fernandez LA, Santos I, Rabadan L, Gutierrez M: Prevalence of abnormal levels of serum tumour markers in elderly people. Age Ageing 25: 45–50, 1996.PubMedCrossRefGoogle Scholar
  21. 21.
    Takami M, Sakamoto H, Ohtani K, Takami T, Satoh K: An evaluation of CA125 levels in 291 normal postmenopausal and 20 endometrial adenocarcinoma-bearing women before and after surgery. Cancer Lett 121: 69–72, 1997.PubMedCrossRefGoogle Scholar
  22. 22.
    Hornstein MD, Goodman HM, Thomas PP, Knapp RC, Harlow BL: Use of a second-generation CA125 assay in gynecologic patients. Gynecol Obstet Invest 42: 196–200, 1996.PubMedCrossRefGoogle Scholar
  23. 23.
    Cengiz B, Atabekoglu C, Cetinkaya E, Cengiz SD: Effect of hormone replacement therapy on serum levels of tumor markers in healthy postmenopausal women. Maturitas 46: 301–306, 2003.PubMedCrossRefGoogle Scholar
  24. 24.
    Menzin AW, Kobrin S, Pollak E, Goodman DB, Rubin SC: The effect of renal function on serum levels of CA125. Gynecol Oncol 58: 375–377, 1995.PubMedCrossRefGoogle Scholar
  25. 25.
    Brekelmans CT: Risk factors and risk reduction of breast and ovarian cancer. Curr Opin Obstet Gynecol 15: 63–68, 2003.PubMedCrossRefGoogle Scholar
  26. 26.
    Grover S, Quinn MA, Weideman P, Koh H: Factors influencing serum CA 125 levels in normal women. Obstet Gynecol 79: 511–514, 1992.PubMedGoogle Scholar
  27. 27.
    Johnson KC, Hu J, Mao Y: Passive and active smoking and breast cancer risk in Canada. Cancer Causes Control 11: 211–221, 2000.PubMedCrossRefGoogle Scholar

Copyright information

© Arányi Lajos Foundation 2007

Authors and Affiliations

  • Alamtaj Samsami Dehaghani
    • 1
  • Alireza Fotouhi Ghiam
    • 2
  • Marjan Hosseini
    • 1
  • Sareh Mansouri
    • 1
  • Abbas Ghaderi
    • 2
    • 3
  1. 1.Department of Obstetrics and GynecologyShiraz University of Medical SciencesShirazIran
  2. 2.Shiraz Institute for Cancer Research (ICR)Shiraz University of Medical SciencesShirazIran
  3. 3.Department of ImmunologyShiraz University of Medical SciencesShirazIran

Personalised recommendations